Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

Mélanie Pouget,Catherine Abrial,E. Planchat,Isabelle Van Praagh,Marie Arbre,Fabrice Kwiatkowski,P. Dubray-Longeras,H. Devaud,Joyce Dohou,Pauline Herviou,Hakim Mahammedi,Xavier Durando,P. Chollet,Marie-Ange Mouret-Reynier

Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

2015

Mélanie Pouget
Catherine Abrial
E. Planchat
Isabelle Van Praagh
Marie Arbre
Fabrice Kwiatkowski
P. Dubray-Longeras
H. Devaud
Joyce Dohou
Pauline Herviou
Hakim Mahammedi
Xavier Durando
P. Chollet
Marie-Ange Mouret-Reynier

Background: Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal wo

Keywords:

Breast cancer
Targeted therapy
Medicine
Exemestane
Tamoxifen
Hormonal therapy
Oncology
Internal medicine
Everolimus
Metastatic breast cancer
Survival rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations